 BALTIMORE--BUSINESS WIRE--MyMD Pharmaceuticals, Inc. Nasdaq: MYMD, a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, announced today that researchers from the Johns Hopkins University School of Medicine will present the results of new research on the companys compound Supera-CBD at the 3rd Annual Neuroimmunology Drug Development Summit. The poster presentation will discuss the preclinical cannabidiol CBD d 